Cannabis ingredient holds promise as antipsychotic medicine
An ingredient in cannabis called cannabidiol or CBD has shown promise in a clinical trial as a potential new treatment for psychosis, scientists said on Friday.
Scientists conducted a small trial of people with psychosis and found patients treated with CBD had lower levels of psychotic symptoms than those who received a placebo. Psychosis is characterised by paranoia and hallucinations.
The study found that they were also more likely to be rated as “improved” by their psychiatrist and there were signs of better cognitive performance and functioning.